 |
|
|
| |
Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir
|
| |
| |
AASLD November 8-12, 2019, Boston, Massachusetts
Ira M Jacobson1, Tania M Welzel2, Douglas E Dylla3, Anne F Luetkemeyer4, Jordan J Feld5, Christophe Moreno6, David Nelson7, Georgios Papatheodoridis8, Juergen K Rockstroh9, Eric Crown3, Sandra S Lovell3, Ashley Brown101NYU Langone Medical Health, New York, New York, United States; 2JW Goethe University Hospital, Frankfurt, Germany; 3AbbVie Inc, North Chicago, Illinois, United States; 4Zuckerberg San Francisco General, University of California at San Francisco, San Francisco, California, United States; 5Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada; 6Departement de Gastroenterologie, d'Hepatopancreatologie et Cancerologie Digestive, CUB Hopital Erasme, Universite Libre de Bruxelles, Bruxelles, Belgium; 7Department of Medicine, University of Florida, Gainesville, Florida, United States; 8Medical School of National and Kapodistrian University of Athens, Athens, Greece; 9Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Bonn, Germany; 10Imperial College Healthcare NHS Trust, London, United Kingdom
|
| |
|
|
|
|
|
